Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 2/20 | 0.46 |
| ▸ | CKS1B | P61024 | 2/20 | 0.44 |
| ▸ | SKP1 | P63208 | 2/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14973123 | 0.83 | GPR119 (0.55) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL624511 | 0.81 | GPR119 (0.52) | GPR119MAP4K4ACACBCKS1BSKP1 | |
| SCHEMBL3103887 | 0.80 | GPR119 (0.51) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL1066568 | 0.79 | GPR119 (0.57) | GPR119 | |
| SCHEMBL2524108 | 0.79 | GPR119 (0.57) | GPR119 | |
| SCHEMBL624296 | 0.79 | GPR119 (0.50) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL3485950 | 0.79 | GPR119 (0.70) | GPR119 | |
| SCHEMBL623305 | 0.79 | GPR119 (0.50) | GPR119MAP4K4ACACBCKS1BSKP1 | |
| SCHEMBL26669649 | 0.78 | GPR119 (0.57) | GPR119MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL1159689 | 0.78 | GPR119 (0.56) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999974-B2 | Acyl piperazine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20130150356-A1 | Acyl Piperazine Derivatives as TTX-S Blockers | RAQUALIA PHARMA INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| WO-2012020567-A1 | ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150356-A1 | Acyl Piperazine Derivatives as TTX-S Blockers | SCN5A, SCN2A, CACNA1G | GPR119 2377/4885MAP4K4 3685/4885ACACB 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.